Viatris’ Mylan and its partner Natco Pharma have put aside a key legal hurdle to their proposed US generic version of Novo Nordisk’s Ozempic (semaglutide) mega blockbuster GLP-1 agonist to treat 2 diabetes – the world’s best-selling diabetes medicine.
The generics firms have reached an agreement settling patent litigation proceedings pending before the US Patent and Trademark Office’s
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?